PATIENT'S PERSPECTIVES ON THE ACCEPTABILITY AND FEASIBILITY OF A SCREEN-AND-TREAT APPROACH TO HPV TREATMENT IN IQUITOS, PERU. (ID 420)

Presenter
Authors

Previous ePoster
EVALUATING HETEROGENEITY IN THE TIMELINE AND COST-EFFECTIVENESS OF CERVICAL CANCER ELIMINATION ACROSS CHINA: A REGIONAL MODELLING APPROACH (ID 314)

Next ePosters
NATIONAL POPULATION AND FAMILY DEVELOPMENT BOARD (NPFDB): OUR JOURNEY IN COMBATING AND ELIMINATING CERVICAL CANCER - FINDINGS AND SUMMARY (ID 424)
SQUAMOUS COLUMNAR JUNCTION VISIBILITY AMONG WLHIV AGED 25-54 YEARS ATTENDING HPV-BASED SCREEN-AND-TREAT IN THE CESTA STUDY (ID 520)
HOW FAR FROM STRATEGIES TO ACCELERATE THE ELIMINATION OF CERVICAL CANCER IS A REGION LOCATED IN THE HEART OF THE BRAZILIAN AMAZON? (ID 609)
RESEARCH ABOUT DISEMINATION AND IMPLEMENTATION OF WHO GUIDELINES FOR CERVICAL CANCER SCREENING, DIAGNOSIS AND TREATMENT: THE GUIDES PROJECT (ID 634)
EFFECT OF HEALTH EDUCATION ON THE KNOWLEDGE OF HUMAN PAPILLOMAVIRUS, CERVICAL CANCER AND SELF-SAMPLING AMONG WOMEN IN RURAL DELTA STATE, NIGERIA. (ID 712)
PREVENTION DURING A PANDEMIC: HOW A PANDEMIC AFFECTED A COMMUNITY HPV VACCINATION PROGRAM ALONG THE US-MEXICO BORDER (ID 159)
HPV PREVENTION: A MASS VACCINATION EXPERIENCE DURING COVID-19 PANDEMIC IN ITALY (ID 188)
A NATIONWIDE CROSS-SECTIONAL SURVEY ON KNOWLEDGE, ATTITUDE AND PRACTICE TOWARDS HUMAN PAPILLOMAVIRUS (HPV) VACCINE IN CHINESE DURING COVID-19 PANDEMIC (ID 490)
STATE-LEVEL VARIABILITY IN HPV VACCINE COVERAGE IN BRAZIL FROM 2018 THROUGH THE COVID-19 PANDEMIC IN 2020 (ID 652)
DISRUPTION TO ADOLESCENT WELL VISITS AND HPV VACCINATIONS DURING THE COVID-19 PANDEMIC (ID 828)